NR1H2 and early-onset autosomal dominant Alzheimer disease: Previous research has shown that LXRβ agonists have significant anti‐inflammatory and neuroprotective effects in various neurodegenerative disease models (such as Alzheimer's disease, Parkinson's disease, and stroke) [22, 23, 24].